• Logo
  • SBMUJournals

Estimation the direct cost of inflammatory bowel disease in Iranian patients: the one-year follow-up

Hedieh Balaii, Meysam Olfatifar, Sepideh Olianasab Narab, Asghar Arab Hosseini, Ali Seyed Salehi, Shabnam Shahrokh




Aim: We conducted this study to estimate the direct medical cost of the Iranian IBD patients.

Background: In the economic evaluation setting, descriptive epidemiological studies can provide substantial information for health system policymakers in taking accountable decisions for diseases such as Inflammatory Bowel Disease (IBD).

Methods: To do so, we used a self-designed checklist to collect demographic and medical cost information for IBD patients. We also tried to have a national estimation of IBD costs.

Results: The mean annual medical cost of IBD was 18354.52 PPP$. Crohn's disease (CD) vs. ulcerative colitis (UC) and UC township patients vs. Tehran residents patients had higher medical costs (31160.79 PPP$; P<0.001) and (20840.23 PPP$, P<0.025). The most spent medical cost in both IBD subtypes (CD/UC) was attributed to biological agents, especially in UC patients. We estimated that the mean annual cost of IBD in Iran for 2017 was 746315864 (602964172, 964685749) PPP$(constant incidence) and 862776811 (697055402, 1115222835) PPP$(increment incidence) respectively. If we assume the constant incidence from 2012 to 2017 the prevalence and subsequently mean annual cost of IBD in 2017 were 66.95 per 100000 and 746315864(602964172, 964685749) PPP$. The prevalence and mean annual cost of IBD for another scenario were 77.39 per 100000 and 862776811(697055402, 1115222835) PPP$ respectively.


Conclusion: Our results suggest that to the management of IBD patient's policymakers should consider shifting the medical costs to biological agents, the higher cost of CD and the impact of underlying factors on the distribution of these medical costs.


Inflammatory bowel disease; Medical cost; Crohn's disease; Ulcerative colitis


Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: A single centre retrospective study. Gut. 2004;53(10):1471–8.

Loftus E V. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology [Internet]. 2004;126(6):1504–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15168363

Jean L, Audrey M, Beauchemin C. Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review [Internet]. Vol. 2018, Canadian Journal of Gastroenterology and Hepatology. Hindawi Limited; 2018 [cited 2019 Apr 27]. p. 7439730. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30009158

Baumgart DC, Sandborn WJ. Infl ammatory bowel disease : clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641–57.

Ganz ML, Sugarman R, Wang R, Hansen BB, Hakan-Bloch J. The economic and health-related impact of Crohn’s disease in the United States: Evidence from a nationally representative survey. Inflamm Bowel Dis. 2016;22(5):1032–41.

Burisch J, Vardi H, Pedersen N, Brinar M, Cukovic-Cavka S, Kaimakliotis I, et al. Costs and resource utilization for diagnosis and treatment during the initial year in a european inflammatory bowel disease inception cohort: An ECCO-EpiCom study. Inflamm Bowel Dis. 2015;21(1):121–31.

Hu P-J. Inflammatory Bowel Disease in Asia: The Challenges and Opportunities. Intest Res. 2015;13(3):188.

Malekzadeh MM, Vahedi H, Gohari K, Mehdipour P, Sepanlou SG, Daryani NE, et al. Emerging epidemic of inflammatory bowel disease in a middle income country: A nation-wide study from Iran. Arch Iran Med. 2015/12/26. 2016;19(1):no pagination.

Bodger K. Cost of illness of Crohn’s disease. Pharmacoeconomics. 2002/08/07. 2002;20(10):639–52.

Pillai N, Dusheiko M, Burnand B, Pittet V. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One [Internet]. 2017;12(10):e0185500. Available from: https://doi.org/10.1371/journal.pone.0185500

Odes S, Greenberg D. A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. Clin Outcomes Res. 2014/10/23. 2014;6:431–43.

Safarpour AR, Hosseini SV, Mehrabani D. Epidemiology of inflammatory bowel diseases in iran and Asia; a mini review. Iran J Med Sci [Internet]. 2013 Jun [cited 2019 Apr 27];38(2 Suppl):140–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24031103

Kamat N, Ganesh Pai C, Surulivel Rajan M, Kamath A. Cost of Illness in Inflammatory Bowel Disease. Dig Dis Sci. 2017;62(9):2318–26.

Mak L, Ng SC, Wong IOL, Li MKK, Lo FH, Wong MTL, et al. Direct health‐care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis. 2018;33(1):141–9.

Burisch J, Jess T, Martinato M, Lakatos PL. The burden of inflammatory bowel disease in Europe. J Crohn’s Colitis [Internet]. 2013;7(4):322–37. Available from: http://www.sciencedirect.com/science/article/pii/S1873994613000305

Shi L, Hodges M, Drummond M, Ahn J, Li SC, Hu S, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: An international perspective: The ISPOR drug cost task force report - Part VI. Value Heal. 2010;13(1):28–33.

Shalmani HM, Soori H, Mansoori BK, Vahedi M, Moghimi-Dehkordi B, Pourhoseingholi MA, et al. Direct and indirect medical costs of functional constipation: A population-based study. Int J Colorectal Dis. 2010/10/20. 2011;26(4):515–22.

Moghimi-Dehkordi B, Vahedi M, Pourhoseingholi MA, Khoshkrood Mansoori B, Safaee A, Habibi M, et al. Economic burden attributable to functional bowel disorders in Iran: A cross-sectional population-based study. J Dig Dis. 2011/10/01. 2011;12(5):384–92.

Ashtari S, Vahedi M, Pourhoseingholi MA, Karkhane M, Kimiia Z, Pourhoseingholi A, et al. Direct medical care costs associated with patients diagnosed with chronic HCV. Hepat Mon. 2013/08/10. 2013;13(5):e8415.

Mak LY, Ng SC, Wong IOL, Li MKK, Lo FH, Wong MTL, et al. Direct health-care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis. J Gastroenterol Hepatol. 2018;33(1):141–9.

Djakovic L, Janković SM, Kostić M, Godman B, Šujić R. Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications. Appl Health Econ Health Policy. 2016;15(1):85–93.

Blomqvist P, Ekbom A. Inflammatory bowel diseases: Health care and costs in Sweden in 1994. Scand J Gastroenterol. 1997;32(11):1134–9.

Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci [Internet]. 2012/08/29. 2013;58(2):519–25. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22926499

Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, et al. The Prevalence and Geographic Distribution of Crohn’s Disease and Ulcerative Colitis in the United States. Clin Gastroenterol Hepatol. 2007;5(12):1424–9.

Shivashankar R, Tremaine WJ, Harmsen WS, Loftus E V. Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010. Clin Gastroenterol Hepatol [Internet]. 2016/11/14. 2017;15(6):857–63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27856364

Schoepfer A, Vavricka S, Bruengger B, Reich O, Blozik E, Bähler C. Systematic analysis of annual health resource utilisation and costs in hospitalised inflammatory bowel disease patients in Switzerland. J Crohn’s Colitis. 2018;12(supplement_1):S328–9.

M’Koma AE. Inflammatory bowel disease: An expanding global health problem. Clin Med Insights Gastroenterol [Internet]. 2013;6:33–47. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24833941

Nguyen NH, Khera R, Ohno-Machado L, Sandborn WJ, Singh S. Annual Burden and Costs of Hospitalization for High-Need, High-Cost Patients With Chronic Gastrointestinal and Liver Diseases. Clin Gastroenterol Hepatol. 2018;16(8):1284-1292.e30.

Borren NZ, Conway G, Tan W, Andrews E, Garber JJ, Yajnik V, et al. Distance to Specialist Care and Disease Outcomes in Inflammatory Bowel Disease. Inflamm Bowel Dis [Internet]. 2017;23(7):1234–9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28520589

Bernstein CN, Longobardi T, Finlayson G, Blanchard JF. Direct medical cost of managing IBD patients: A Canadian population-based study. Inflamm Bowel Dis. 2012;18(8):1498–508.

Dulai PS, Singh S, Ohno-Machado L, Sandborn WJ. Population Health Management for Inflammatory Bowel Disease. Gastroenterology. 2017/11/11. 2018;154(1):37–45.

Pedersen N. EHealth: Self-management in inflammatory bowel disease and in irritable bowel syndrome using nov-el constant-care web applications. Dan Med J. 2015/12/02. 2015;62(12):B5168.

Petryszyn PW, Witczak I. Costs in inflammatory bowel diseases. Prz Gastroenterol [Internet]. 2016/02/11. 2016;11(1):6–13. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27110304

DOI: https://doi.org/10.22037/ghfbb.v12i0.1824